SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Syndax Pharmaceuticals, Inc
The therapy that will be receive involves being given the drug SNDX-5613 to treat Relapsed/Refractory acute leukemias, including those harboring an KMT2Ar Gene Rearrangement, Nucleophosmin 1 (NPM1m) Mutation or Nucleoporin 98 (NUP98)-rearranged (NUP98r) acute leukemia, or any other genetic alteration with overexpression of HOXA genes predicted to potentially benefit from treatment with SNDX-5613.
Enrollment Form
This study is currently enrolling.